Why Was Sight Sciences Stock Down on Aug 5, 2026?

Sight Sciences (SGHT) is down about 1.6% today, trading near $5.32. There is no new company-specific headline dated today driving the move — this is the continuation of a reversal that started the day before.

On August 4, 2026, Sight Sciences announced FDA 510(k) clearance of its OMNI Ultra Surgical System, the next-generation version of its glaucoma treatment platform. Shares jumped 18.544% within a minute of that after-hours release, from $5.77 to $6.84, on thin volume. That pop has now fully unwound: today's price is roughly 22.2% below the after-hours peak, and about 7.8% below where the stock traded before the clearance news broke.

The clearance itself was real — OMNI Ultra is cleared for canaloplasty followed by trabeculotomy to reduce eye pressure in adult primary open-angle glaucoma patients, and the company says it is the first FDA-cleared device to perform that procedure around the full drainage channel in a single pass. But a regulatory clearance is not a sales event: Sight Sciences says OMNI Ultra's commercial launch is not planned until the fourth quarter of 2026, so there is no near-term revenue tied to today's price action either way.

Historical catalyst, for context: on August 4, 2026, SGHT jumped 18.544% after hours on FDA clearance of OMNI Ultra. That is the most recent dated company news; today's move has no new headline attached to it.